Cardiff Oncology (CRDF) Stock Forecast & Price Target

Compare

1,979 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRDF Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Cardiff

Oncology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRDF Stock 12 Month Forecast

Average Price Target

$9.33

▲(415.47% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Cardiff Oncology in the last 3 months. The average price target is $9.33 with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 415.47% change from the last price of $1.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,2.5015384615384617,3.293076923076923,4.084615384615384,4.876153846153846,5.667692307692308,6.459230769230769,7.25076923076923,8.042307692307691,8.833846153846153,9.625384615384615,10.416923076923077,11.208461538461538,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,2.296153846153846,2.882307692307692,3.4684615384615385,4.054615384615385,4.64076923076923,5.226923076923077,5.813076923076923,6.399230769230769,6.985384615384615,7.571538461538461,8.157692307692308,8.743846153846153,{"y":9.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,2.04,2.37,2.7,3.0300000000000002,3.3600000000000003,3.69,4.02,4.35,4.68,5.01,5.34,5.67,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$9.33

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert LeBoyer

Noble Financial

$12

Buy

562.98%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), RxSight (NASDAQ: RXST) and Cardiff Oncology (NASDAQ: CRDF)

Robert Burns

H.C. Wainwright

$10

Buy

452.49%

Upside

Reiterated

02/25/26

Cardiff Oncology: Promising Onvansertib Data and Solid Cash Runway Support Buy Rating and $10 Price Target

Andy Hsieh

William Blair

―

Buy

―

Reiterated

02/25/26

Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), AbCellera Biologics (ABCL)

Edward Tenthoff

Piper Sandler

$10→$6

Buy

231.49%

Upside

Reiterated

02/25/26

Cardiff Oncology (CRDF) Receives a Buy from Piper Sandler

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (NASDAQ: CRDF) and Alphatec Holdings (NASDAQ: ATEC)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

01/27/26

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Cardiff Oncology (NASDAQ: CRDF)

Kevin DeGeeter

Ladenburg Thalmann & Co.

$19

Buy

949.72%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX), BioLife Solutions (NASDAQ: BLFS) and Cardiff Oncology (NASDAQ: CRDF)

Maury Raycroft

Jefferies

$3.5

Hold

93.37%

Upside

Initiated

06/24/25

Cardiff Oncology (CRDF) Receives a New Rating from Jefferies

Christopher Liu

Lucid Capital

$14

Buy

673.48%

Upside

Initiated

04/03/25

Cardiff Oncology initiated with a Buy at Lucid CapitalCardiff Oncology initiated with a Buy at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert LeBoyer

Noble Financial

$12

Buy

562.98%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), RxSight (NASDAQ: RXST) and Cardiff Oncology (NASDAQ: CRDF)

Robert Burns

H.C. Wainwright

$10

Buy

452.49%

Upside

Reiterated

02/25/26

Cardiff Oncology: Promising Onvansertib Data and Solid Cash Runway Support Buy Rating and $10 Price Target

Andy Hsieh

William Blair

―

Buy

―

Reiterated

02/25/26

Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), AbCellera Biologics (ABCL)

Edward Tenthoff

Piper Sandler

$10→$6

Buy

231.49%

Upside

Reiterated

02/25/26

Cardiff Oncology (CRDF) Receives a Buy from Piper Sandler

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (NASDAQ: CRDF) and Alphatec Holdings (NASDAQ: ATEC)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

01/27/26

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Cardiff Oncology (NASDAQ: CRDF)

Kevin DeGeeter

Ladenburg Thalmann & Co.

$19

Buy

949.72%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX), BioLife Solutions (NASDAQ: BLFS) and Cardiff Oncology (NASDAQ: CRDF)

Maury Raycroft

Jefferies

$3.5

Hold

93.37%

Upside

Initiated

06/24/25

Cardiff Oncology (CRDF) Receives a New Rating from Jefferies

Christopher Liu

Lucid Capital

$14

Buy

673.48%

Upside

Initiated

04/03/25

Cardiff Oncology initiated with a Buy at Lucid CapitalCardiff Oncology initiated with a Buy at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cardiff Oncology

3 Months

xxx

Success Rate

7/13 ratings generated profit

Average Return

+1.57%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +1.57% per trade.

1 Year

Marc FrahmTD Cowen

Success Rate

4/13 ratings generated profit

Average Return

-6.34%

reiterated a buy rating 24 days ago

Copying Marc Frahm's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -6.34% per trade.

2 Years

xxx

Success Rate

3/13 ratings generated profit

Average Return

-11.14%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 23.08% of your transactions generating a profit, with an average return of -11.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRDF Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Nov 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRDF has received 16 Buy Ratings, 34 Hold Ratings, and 7 Sell Ratings. CRDF average Analyst price target in the past 3 months is 9.33.

Each month's total comprises the sum of three months' worth of ratings.

CRDF Financial Forecast

CRDF Earnings Forecast

Next quarter’s earnings estimate for CRDF is -$0.14 with a range of -$0.19 to -$0.11. The previous quarter’s EPS was -$0.11. CRDF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CRDF has Performed in-line its overall industry.

CRDF Sales Forecast

Next quarter’s sales forecast for CRDF is $89.00K with a range of $0.00 to $150.00K. The previous quarter’s sales results were $243.00K. CRDF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CRDF has Performed in-line its overall industry.

CRDF Stock Forecast FAQ

What is CRDF’s average 12-month price target, according to analysts?

Based on analyst ratings, Cardiff Oncology, Inc.’s 12-month average price target is 9.33.

What is CRDF’s upside potential, based on the analysts’ average price target?

Cardiff Oncology, Inc. has 415.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRDF a Buy, Sell or Hold?

Cardiff Oncology, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Cardiff Oncology, Inc.’s price target?

The average price target for Cardiff Oncology, Inc. is 9.33. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $6.00. The average price target represents 415.47% Increase from the current price of $1.81.

What do analysts say about Cardiff Oncology, Inc.?

Cardiff Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of CRDF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cardiff Oncology (CRDF) Stock Forecast & Price Target

CRDF Analyst Ratings

CRDF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cardiff Oncology

CRDF Analyst Recommendation Trends

CRDF Financial Forecast

CRDF Earnings Forecast

CRDF Sales Forecast

CRDF Stock Forecast FAQ

Detailed List of Analyst Forecasts